60 DEGREES PHARMA INC (SXTP) Stock Price, Quote, News and Overview
NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD
SXTP Quote, Performance and Key Statistics
3.16
-0.01 (-0.32%)
The current stock price of SXTP is 3.16 USD. In the past month the price increased by 59.6%. In the past year, price decreased by -78.15%.
SXTP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 64.61 | 796.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.67 | 379.48B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 16.83 | 257.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 218.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.29 | 209.55B | ||
| MRK | MERCK & CO. INC. | 10.21 | 196.28B | ||
| PFE | PFIZER INC | 7.12 | 125.57B | ||
| SNY | SANOFI-ADR | 11.41 | 124.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 43.18 | 100.17B | ||
| GSK | GSK PLC-SPON ADR | 8.32 | 72.88B | ||
| ZTS | ZOETIS INC | 25.11 | 66.32B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 46.47B |
Related stock screener links
About SXTP
Company Profile
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Company Info
60 DEGREES PHARMA INC
1025 Connecticut Avenue Nw, Suite 1000
WASHINGTON WASHINGTON DC US
Employees: 3
Company Website: https://60degreespharma.com/
Investor Relations: https://investors.60degreespharma.com/
Phone: 12023275422
60 DEGREES PHARMA INC / SXTP FAQ
What is the stock price of 60 DEGREES PHARMA INC today?
The current stock price of SXTP is 3.16 USD. The price decreased by -0.32% in the last trading session.
What is the ticker symbol for 60 DEGREES PHARMA INC stock?
The exchange symbol of 60 DEGREES PHARMA INC is SXTP and it is listed on the Nasdaq exchange.
On which exchange is SXTP stock listed?
SXTP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 60 DEGREES PHARMA INC stock?
8 analysts have analysed SXTP and the average price target is 17.34 USD. This implies a price increase of 448.73% is expected in the next year compared to the current price of 3.16. Check the 60 DEGREES PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 60 DEGREES PHARMA INC worth?
60 DEGREES PHARMA INC (SXTP) has a market capitalization of 4.65M USD. This makes SXTP a Nano Cap stock.
How many employees does 60 DEGREES PHARMA INC have?
60 DEGREES PHARMA INC (SXTP) currently has 3 employees.
What are the support and resistance levels for 60 DEGREES PHARMA INC (SXTP) stock?
60 DEGREES PHARMA INC (SXTP) has a support level at 1.92 and a resistance level at 3.46. Check the full technical report for a detailed analysis of SXTP support and resistance levels.
Is 60 DEGREES PHARMA INC (SXTP) expected to grow?
The Revenue of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 109.78% in the next year. Check the estimates tab for more information on the SXTP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy 60 DEGREES PHARMA INC (SXTP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SXTP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SXTP, evaluating the profitability, health, valuation and growth aspects
- 60 DEGREES PHARMA INC (SXTP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 60 DEGREES PHARMA INC (SXTP) Sales and EPS estimates to see what analysts future expectations are.
- 60 DEGREES PHARMA INC (SXTP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 60 DEGREES PHARMA INC (SXTP) Insider and Institutional Ownership to learn about the owners and their transactions.
- 60 DEGREES PHARMA INC (SXTP) Stock Chart to make your own analysis
- 60 DEGREES PHARMA INC (SXTP) Latest news and press-releases to stay up to date.
Does 60 DEGREES PHARMA INC (SXTP) stock pay dividends?
SXTP does not pay a dividend.
What is the Price/Earnings (PE) ratio of 60 DEGREES PHARMA INC (SXTP)?
60 DEGREES PHARMA INC (SXTP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.64).
SXTP Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SXTP. When comparing the yearly performance of all stocks, SXTP is a bad performer in the overall market: 92.56% of all stocks are doing better.
SXTP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SXTP. The financial health of SXTP is average, but there are quite some concerns on its profitability.
SXTP Financial Highlights
Over the last trailing twelve months SXTP reported a non-GAAP Earnings per Share(EPS) of -39.64.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113% | ||
| ROE | -138.85% | ||
| Debt/Equity | 0.02 |
SXTP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SXTP. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 77.95% and a revenue growth 109.78% for SXTP